NJ

Namita Jena

Active Director Director DIN 10539505
DIN 10539505 First appointment Feb 2024 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2024
Shareholding value •••• Premium profile

About Namita Jena

Data last updated:

Namita Jena is a Director at Oro Pharmaceuticals Private Limited (since 2024). The company operates in Pharma. Oro Pharmaceuticals Private Limited reported revenue of ₹1.29 Cr (FY 2025).

DIN 10539505
Primary Designation Director
Industry Pharma
First Appointment 19 Feb 2024
Oldest Company Age 22 yrs
Largest company Oro Pharmaceuticals Private Limited · ₹1.29 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Oro Pharmaceuticals Private Limited U24232OR2004PTC007517
Director19 Feb 20242004₹1.29 Cr (FY 2025)Active

Board colleagues of Namita Jena

Directorship timeline

Open interactive timeline →
Oro Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Namita Jena

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Namita Jena

Namita Jena currently holds 1 directorship: Oro Pharmaceuticals Private Limited (Director, since 19 Feb 2024, revenue ₹1.29 Cr (FY 2025)).

Namita Jena was first appointed on 19 Feb 2024 as Director at Oro Pharmaceuticals Private Limited.

The current boards of Namita Jena's companies include Akshaya Kumar Jena (Oro Pharmaceuticals Private Limited), Saswat Anumeya Jena (Oro Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available